Material Safety Data Sheet Section 1. Identification of the substance Product Name: 2,4,6-Tribromopyridine Synonyms: Section 2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section 3. Composition/information on ingredients. Ingredient name: 2,4,6-Tribromopyridine CAS number: 2408-70-0 Section 4. First aid measures Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section 5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section 6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution: Wear approved mask/respirator Hand precaution: Wear suitable gloves/gauntlets Skin protection: Wear suitable protective clothing Eye protection: Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section 7. Handling and storage Handling: This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels. Storage: Section 8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section 9. Physical and chemical properties Appearance: Not specified Boiling point: No data No data Melting point: Flash point: No data Density: No data Molecular formula: C5H2Br3N Molecular weight: 315.8 Section 10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide. Section 11. Toxicological information No data. Section 12. Ecological information No data. Section 13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section 14. Transportation information Non-harzardous for air and ground transportation. Section 15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313.
[EN] COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS COMME INHIBITEURS DE PROTÉINES KINASES
申请人:NOVARTIS AG
公开号:WO2016038582A1
公开(公告)日:2016-03-17
The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
The organic palladium complex (trans-dichlorobis(4-iodoaniline-κN)palladium(II)) was encapsulated into a porous metal–organicframework MIL-Cr (Pd complex@MIL-Cr) using ship-in-a-bottle strategy. The novel catalyst as a three dimensional nanoreactor was fully characterized using different techniques such as XRD, BET, XPS, SEM, EDX, TEM and ICP. The Pd complex@MIL-Cr is isostructural to the parent MIL-Cr
有机钯配合物(反式-二氯双(4-碘苯胺-κN)钯(II))通过瓶装策略封装在多孔的金属有机框架MIL-Cr(Pd complex @ MIL-Cr)中。使用不同的技术,如XRD,BET,XPS,SEM,EDX,TEM和ICP,对新型作为三维纳米反应器的催化剂进行了全面表征。Pd complex @ MIL-Cr与母体MIL-Cr骨架是同构的,具有约200的高表面积和孔体积。1418 m 2 g -1和0.87 cm 3 g -1, 分别。纳米反应器在芳基卤化物的催化转化中非常高效,显示出比均相Pd对应物更高的活性。出乎意料的是,在具有广泛取代基的氯代芳烃的Suzuki-Miyaura和Heck偶联反应中实现了高收率。此外,该方案可以扩展到2-溴和2,6-二溴吡啶与芳基硼酸的交叉偶联,在室温下具有优异的收率。Pd配合物@ MIL-Cr还用作制备一系列C 3的高效便捷催化剂以苯,吡啶或嘧啶单元
Cercosporin-bioinspired photoreductive activation of aryl halides under mild conditions
here we took advantage of the photophysical properties of cercosporin, and used it as a metal-free photocatalyst to develop an unprecedented cercosporin-driven photocatalysis under mild conditions. Furthermore, the forming conditions and excited-state dynamics of radical anions of cercosporin have been systematically investigated. In particular, transient femtosecond absorption spectroscopy was employed
Novel compounds of the general formula (I), in which the variables are as defined in claim
1
, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.
[EN] NOVEL COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] NOUVEAUX COMPOSES, LEUR PREPARATION ET LEUR UTILISATION
申请人:NOVO NORDISK AS
公开号:WO2005105726A1
公开(公告)日:2005-11-10
Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.